ELVN - Enliven Therapeutics Inc
IEX Last Trade
21.88
-0.340 -1.554%
Share volume: 137,597
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$22.22
-0.34
-1.53%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-4.87%
1 Month
-16.26%
3 Months
-2.93%
6 Months
28.71%
1 Year
39.10%
2 Year
337.60%
Key data
Stock price
$21.88
DAY RANGE
$21.32 - N/A
52 WEEK RANGE
$9.80 - $27.67
52 WEEK CHANGE
$0.33
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO:
Region: US
Website:
Employees: 31
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website:
Employees: 31
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
enliven therapeutics focuses on the discovery and development of next generation small molecule treatments for cancer. we are backed by top-tier life science venture funds. we seek experienced and passionate drug hunters to join our team as we grow our r&d organization in boulder, co.
Recent news